Molgramostim 300 mcg nebuliser solution    (DrugBank: Molgramostim)

1 disease
IDDisease name (Link within this page)Number of trials
229Autoimmune pulmonary alveolar proteinosis3

229. Autoimmune pulmonary alveolar proteinosis    [ 35 clinical trials,   30 drugs,   (DrugBank: 8 drugs),   3 drug target genes,   12 drug target pathways]
Searched query = "Autoimmune pulmonary alveolar proteinosis", "Congenital pulmonary alveolar proteinosis", "Hereditary pulmonary alveolar proteinosis", "Pulmonary alveolar proteinosis", "PAP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 35 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003878-33-PT
(EUCTR)
16/02/201806/11/2017A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim by inhalation.A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients - IMPALA Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim 300 mcg nebuliser solution
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLNot RecruitingFemale: yes
Male: yes
135Phase 2;Phase 3Portugal;United States;Slovakia;Greece;Spain;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Poland;Australia;Denmark;Netherlands;Germany;Japan;Korea, Republic of
2EUCTR2015-003878-33-NL
(EUCTR)
19/01/201628/10/2015A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim by inhalation.A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients - IMPALA Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000015560;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim 300 mcg nebuliser solution
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLNot RecruitingFemale: yes
Male: yes
90Phase 2;Phase 3United States;Portugal;Slovakia;Greece;Spain;Turkey;Israel;Russian Federation;United Kingdom;Switzerland;Italy;France;Belgium;Poland;Denmark;Netherlands;Germany;Japan;Korea, Republic of
3EUCTR2015-003878-33-DK
(EUCTR)
11/12/201523/10/2015A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim by inhalation.A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients - IMPALA Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000015560;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Molgramostim 300 mcg nebuliser solution
INN or Proposed INN: MOLGRAMOSTIM
Savara ApSNULLNot RecruitingFemale: yes
Male: yes
90Phase 2;Phase 3Slovakia;Greece;Spain;Turkey;Israel;Russian Federation;United Kingdom;Switzerland;Italy;France;Belgium;Poland;Denmark;Germany;Netherlands;Japan;Korea, Republic of;United States;Portugal